Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301351 | 0.84 | CXCR2 (0.73) | CXCR2CX3CR1 | |
| SCHEMBL6299806 | 0.84 | CXCR2 (0.73) | CXCR2CX3CR1 | |
| SCHEMBL6649834 | 0.84 | CXCR2 (0.73) | CXCR2CX3CR1 | |
| SCHEMBL6626736 | 0.84 | CXCR2 (0.73) | CXCR2CX3CR1 | |
| SCHEMBL842445 | 0.84 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL842444 | 0.84 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL6299875 | 0.82 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL4494313 | 0.80 | CXCR2 (0.80) | CXCR2CX3CR1 | |
| SCHEMBL842363 | 0.80 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL4485993 | 0.80 | CXCR2 (0.81) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958343-B2 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA, AB (SE) | 2005-10-25 | — | — | US | claimed |
| EP-1257556-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | claimed |
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | US | claimed |
| US-6958343-B2 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA, AB (SE) | 2005-10-25 | — | — | US | disclosed |
| EP-1257556-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | CCR5, CCR2, CXCR4 | CXCR2 5/4885CX3CR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.